Trials / Completed
CompletedNCT05243680
An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)
A Multi-centre, Single Arm, Open-label Extension Study to Evaluate the Long-term Safety of GSK3511294 (Depemokimab) in Adult and Adolescent Participants With Severe Asthma With an Eosinophilic Phenotype From Studies 206713 or 213744
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 641 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this open-label 12-month extension study is to continue to characterize the long-term safety, efficacy and immunogenic profile of GSK3511294 (Depemokimab) in participants with severe asthma with an eosinophilic phenotype following completion of clinical studies 206713 or 213744.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GSK3511294 (Depemokimab) | GSK3511294 (Depemokimab) will be administered using a pre-filled safety syringe. |
Timeline
- Start date
- 2022-03-01
- Primary completion
- 2025-05-19
- Completion
- 2025-05-19
- First posted
- 2022-02-17
- Last updated
- 2026-01-15
- Results posted
- 2026-01-15
Locations
137 sites across 14 countries: United States, Australia, Canada, China, Czechia, France, Germany, Hungary, Italy, Japan, Poland, Spain, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05243680. Inclusion in this directory is not an endorsement.